Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials - PubMed

AbbVie.
pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov